Exelixis Director Stelios Papadopoulos Receives 8,367 RSUs

This Form 4 filing reports that Stelios Papadopoulos, a director of Exelixis, Inc., received 8,367 restricted stock units (RSUs) on May 27, 2026. The RSUs were granted under the company's 2017 Equity Incentive Plan and represent the economic equivalent of common stock. The award will vest in full on May 27, 2027, contingent on Papadopoulos's continued service as a director through that date. Following this transaction, Papadopoulos holds 1,197,595 shares of Exelixis common stock, which includes the 8,367 shares that will be issued upon vesting of the RSUs. The RSUs were granted at $0 per share, consistent with equity compensation awards. This filing provides transparency about director compensation and equity holdings in the biotechnology company.